Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials

SIMPLE SUMMARY: Monoclonal antibodies targeting HER2 are used for the management of early and metastatic HER2-positive breast cancer. Approximately 10–15% of patients diagnosed with breast cancer will be HER2-positive. The incidence of heart failure in breast cancer patients is becoming increasingly...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Lauren J., Meredith, Thomas, Yu, Jie, Patel, Anushka, Neal, Bruce, Arnott, Clare, Lim, Elgene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583665/
https://www.ncbi.nlm.nih.gov/pubmed/34771689
http://dx.doi.org/10.3390/cancers13215527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583665/
https://www.ncbi.nlm.nih.gov/pubmed/34771689
http://dx.doi.org/10.3390/cancers13215527

Ejemplares similares